Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

NCT02819518 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

882

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer (TNBC)

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Nab-paclitaxel
DRUG: Paclitaxel
DRUG: Gemcitabine
DRUG: Carboplatin
DRUG: Normale Saline Solution

Sponsor

Merck Sharp & Dohme LLC